Northrop Grumman Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Northrop Grumman Corporation trades at $512.35 (market cap $74.42B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: Northrop Grumman Corporation pays a 1.79% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Northrop Grumman Corporation nearer its low. Which is the better fit depends on your goals.
| NOC | XBI | |
|---|---|---|
Market Cap | $74.42B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $768.02 | $164.28 |
52-Week Low | $496.02 | $85.16 |
Enterprise Value | $88.65B | — |
Dividend Yield | 1.79% | — |
Trailing returns across standard periods
Latest headlines on both assets
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →